Organon (OGN) Proxy filing summary

Executive summary

• Entered into a definitive agreement to be acquired by Sun Pharma, reflecting validation of recent growth and achievements.

• Operations, leadership, and strategic priorities will remain unchanged until the transaction closes.

• Continued focus on product launches and expansion, including Nexplanon, VTAMA, Miudella, and biosimilars.

• Commitment to transparent communication throughout the acquisition process.

• Forward-looking statements highlight expectations and risks related to the merger, including timing, completion, and potential impacts.

Voting matters and shareholder proposals

• Stockholders will be asked to approve the merger with Sun Pharma; proxy materials and voting instructions will be provided.

• Competing offers or acquisition proposals may be considered if presented.

Board of directors and corporate governance

• Leadership continuity is planned, with the current CEO and Executive Chair remaining in their roles during the transition.

• Directors, executive officers, and employees may be deemed participants in the proxy solicitation for the acquisition.